|
The uptick in demand for HRT comes shortly after the FDA removed their long-standing associated black box label warning.
|
 |
|
The FDA is looking to modernise its regulatory framework for drugs derived from plants, algae, and fungi.
|
|
|
At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.
|
|
|
Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026.
|
|
|
The arrangement aims to use Médunik Canada’s expertise in rare diseases to boost relationships with Canadian epilepsy specialists and centres.
|
|
